{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:17:28Z","timestamp":1783189048915,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jgar.2017.05.025","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T16:30:29Z","timestamp":1500481829000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013\u20132015)"],"prefix":"10.1016","volume":"10","author":[{"given":"M.A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgar.2017.05.025_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.05.025_bib0010","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1086\/320182","article-title":"Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region","volume":"32","author":"Winokur","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2017.05.025_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.jgar.2017.05.025_bib0020","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2013.280695","article-title":"Report reveals scope of US antibiotic resistance threat","volume":"310","author":"Hampton","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2017.05.025_bib0025","unstructured":"Antimicrobial resistance surveillance report Europe 2013. [database on the Internet] 2014. Available from: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-surveillance-europe-2013.pdf. [Accessed June 2016]."},{"issue":"7","key":"10.1016\/j.jgar.2017.05.025_bib0030","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2017.05.025_bib0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.47102\/annals-acadmedsg.V37N10p819","article-title":"Antibiotic resistance in gram-negative bacilli: a Singapore perspective","volume":"37","author":"Tan","year":"2008","journal-title":"Ann Acad Med Singapore"},{"issue":"6","key":"10.1016\/j.jgar.2017.05.025_bib0040","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bjid.2013.07.002","article-title":"Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)","volume":"17","author":"Jones","year":"2013","journal-title":"Braz J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.05.025_bib0045","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2017.05.025_bib0050","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cir475","article-title":"Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections\u2014proceedings and data from the Gram-Negative Resistance Summit","volume":"53","author":"Kollef","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2017.05.025_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"10.1016\/j.jgar.2017.05.025_bib0060","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/CCM.0000000000001140","article-title":"Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis","volume":"43","author":"Zhang","year":"2015","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jgar.2017.05.025_bib0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jhin.2005.07.009","article-title":"Economic burden associated with multi-resistant gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital","volume":"62","author":"Daxboeck","year":"2006","journal-title":"J Hosp Infect"},{"issue":"12","key":"10.1016\/j.jgar.2017.05.025_bib0070","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10x \u201820 progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.05.025_bib0075","first-page":"787","article-title":"Critical evaluation of ceftolozane\u2013tazobactam for complicated urinary tract and intra-abdominal infections","volume":"12","author":"Giancola","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.jgar.2017.05.025_bib0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation beta-lactam\/beta-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jgar.2017.05.025_bib0085","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jgar.2017.05.025_bib0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.jgar.2017.05.025_bib0095","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u20132012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2017.05.025_bib0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.jgar.2017.05.025_bib0105","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.05.025_bib0110","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition","author":"CLSI","year":"2015"},{"key":"10.1016\/j.jgar.2017.05.025_bib0115","series-title":"M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"CLSI","year":"2016"},{"key":"10.1016\/j.jgar.2017.05.025_bib0120","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, January 2016. [database on the Internet]. European Committee on Antimicrobial Susceptibility Testing. 2016. Available from: http:\/\/www.eucast.org\/clinical_breakpoints\/. [Accessed January 2016]."},{"issue":"3","key":"10.1016\/j.jgar.2017.05.025_bib0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jgar.2017.05.025_bib0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0732-8893(01)00353-4","article-title":"Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998\u201399)","volume":"42","author":"Bell","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2017.05.025_bib0135","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.33321\/cdi.2016.40.18","article-title":"Australian group on antimicrobial resistance Australian Enterobacteriaceae sepsis outcome programme annual report, 2014","volume":"40","author":"Bell","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"issue":"6","key":"10.1016\/j.jgar.2017.05.025_bib0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jinf.2010.03.024","article-title":"The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)","volume":"60","author":"Farrell","year":"2010","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jgar.2017.05.025_bib0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2005.04.004","article-title":"Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002)","volume":"52","author":"Hirakata","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2017.05.025_bib0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","article-title":"The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance","volume":"25","author":"Jones","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2017.05.025_bib0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2009.06.003","article-title":"Increasing extended-spectrum beta-lactamase production and quinolone resistance among gram-negative bacilli causing intra-abdominal infections in the Asia\/Pacific region: data from the Smart Study 2002\u20132006","volume":"59","author":"Ko","year":"2009","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jgar.2017.05.025_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:14:45Z","timestamp":1750781685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":32,"alternative-id":["S2213716517301133"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.05.025","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013\u20132015)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}